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Inﬂ iximab or ciclosporin for acute severe ulcerative colitis?
Acute severe ulcerative colitis remains one of the 
most challenging patient populations to treat. Despite 
signiﬁ cant therapeutic advances that have resulted in 
higher rates of remission and lower rates of surgery in 
patients with Crohn’s disease and ulcerative colitis,1 
this improvement in outcomes is modest in those 
with severe disease requiring hospitalization, and 
rates of treatment response remain inadequate.2 
There exist two eﬀ ective options for treating steroid 
refractory acute severe ulcerative colitis—ciclosporin 
and inﬂ iximab—both of which have individually 
established eﬃ  cacy in the short and medium terms in 
rigorously conducted randomised controlled trials.3,4 
However until recently, there was little data on the 
comparative eﬃ  cacy of both agents and choice was 
informed primarily by individual and institutional 
experience. In 2012, Laharie and colleagues5 published 
the CYSIF trial, the ﬁ rst open-label randomised trial 
including 115 patients with steroid refractory acute 
severe ulcerative colitis, randomised to ciclosporin 
or inﬂ iximab. Rates of treatment failure and need for 
colectomy were similar in both groups at the end of 
98 days. In The Lancet Gastroenterology & Hepatology, 
Williams and colleagues6 present the results of a 
second trial—CONSTRUCT—similarly comparing 
inﬂ iximab and ciclosporin for acute steroid refractory 
colitis. Adopting a pragmatic design, the authors 
select a primary outcome of quality-adjusted survival, 
deﬁ ned as the area under the curve described by 
the score from the Crohn’s and Ulcerative Colitis 
Questionnaire till year 3. Secondary outcomes included 
changes in general quality of life (using EQ-5D and 
SF-12 scales), need for surgery, length of stay, and 
cost-eﬀ ectiveness. 270 patients were recruited from 
52 hospitals over the 3 years of the study (135 in each 
group) with the primary outcome being analysable in 
242 patients. Over a median follow-up of 765 days, 
there was no diﬀ erence in quality-adjusted survival 
between the two groups (p=0.63). For secondary 
outcomes, there was no diﬀ erence in the proportion 
requiring colectomy (41% with inﬂ iximab vs 48% with 
cyclosporine, p=0.223) or in time to colectomy, and 
no diﬀ erences were noted in adverse eﬀ ects between 
both groups. The cost-eﬀ ectiveness analysis showed 
signiﬁ cantly higher health-care costs with inﬂ iximab.
The novel pragmatic trial design and quality-adjusted 
survival as outcomes are directly relevant to real-
world practice, where restoration of normal quality of 
life is an important goal of therapy in inﬂ ammatory 
bowel diseases, and cost-eﬀ ectiveness of treatment 
strategies is an important determinant of position of 
various therapies in the treatment pyramid. However, 
a few aspects of the trial design leave some important 
key questions unanswered. Many of the endpoints we 
now recognize as important in inﬂ ammatory bowel 
diseases, such as mucosal healing and quantiﬁ cation 
of disease activity (through clinical or proxy measures 
such as calprotectin or C-reactive protein), are not 
included as outcomes in this trial.7 Time to symptom 
response, an important outcome in the ill, hospitalised 
patient, is also not presented. The use of a quality-of-
life measure as a primary outcome also raises questions 
about the accuracy of a measure to inform comparative 
eﬃ  cacy that is aﬀ ected not just by disease activity (the 
main treatment eﬀ ect) but also substantially by co-
morbidity (eg, depression or functional bowel disease), 
with the potential for both under and over-estimating 
treatment eﬀ ects without an accompanying objective 
endpoint.
Both the CONSTRUCT trial6 and the CYSIF trial5 
are landmark publications in a challenging patient 
population where there is dearth of high-quality 
comparative data. The equivalence of both treatments 
in the two studies provide reassurance to the treating 
clinician about comparability of ciclosporin and 
standard-dose inﬂ iximab, and that choice can continue 
to be determined by provider and institutional 
experience. However, factors in the trial design in 
both trials (inclusion of previously thiopurine-exposed 
patients in the CYSIF trial and lack of a deﬁ ned post-
hospitalisation treatment plan in the CONSTRUCT 
trial) preclude both from being the ﬁ nal answers to 
this question. It is possible that response rates may 
be higher with aggressive optimisation of care. With 
the recognition of substantial fecal loss of inﬂ iximab 
in acute severe ulcerative colitis,8 it is possible that a 
more aggressive upfront inﬂ iximab strategy,9 perhaps 
in conjunction with an immunomodulator, may 
improve the outcomes in inﬂ iximab-treated patients 
with acute severe ulcerative colitis. Furthermore, 
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The therapeutic revolution in therapy for hepatitis C 
virus (HCV) seen in recent years has left some crucial 
gaps, with genotypes other than genotype 1 having 
either less evidence of eﬃ  cacy or proven lower eﬃ  cacy. 
Even with the potential availability of drugs with cure 
rates approaching 100%, it is uncertain how many 
populations across the world will have the ﬁ nance 
and the health system organisation to access these 
therapies.1
Genotype 4 HCV accounts for an estimated 8% of HCV 
infections worldwide, most of which are in Egypt (where 
genotype 4a predominates) and surrounding countries 
of north, central, and east Africa.2 Although fairly 
uncommon in the USA and northern Europe, genotype 
4 is seen increasingly as a result of migration from high-
burden regions.  
The Articles in The Lancet Gastroenterology & 
Hepatology by Tarik Asselah and colleagues3 and 
Imam Waked and colleagues4 provide data to help 
treat patients with genotype 4. Previous studies have 
shown that ombitasvir, paritaprevir, and ritonavir plus 
ribavirin achieves high cure rates in HCV genotype 4 
infection, but doubts about the optimum regimen 
have persisted, mainly because of the small number 
of patients with HCV genotype 4 infection treated 
in the registration trials. One area of uncertainty 
was the duration of treatment needed in patients 
with advanced ﬁ brotic liver disease, in whom a 
longer regimen than the standard 12 weeks has been 
suggested to improve response rates. In AGATE-I, 
Asselah and colleagues3 studied patients with HCV 
genotype 4 infection and cirrhosis who had not 
previously been treated with direct-acting antivirals, 
comparing 12 weeks with 16 weeks of ombitasvir, 
paritaprevir, and ritonavir once daily with weight-
based ribavirin. AGATE-I was done in 120 participants 
in North America and Europe (64 [53%] with genotype 
4a infection; 60 [50%] with treatment experience). 
Cure rates were very high and equivalent in both 
groups (57 [97%] of 59 in the 12-week treatment 
whether the eﬃ  cacy of ciclosporin can be ampliﬁ ed 
by maintenance treatment with agents such as 
vedolizumab remains to be established, having 
demonstrated promise in small cohorts.10 Examination 
of personalised strategies guided by therapeutic drug 
monitoring is essential to further inform our practice 
and improve outcomes in this ill group of patients. 
In parallel, there is the need for clinical, genetic, and 
other -omics based tools that can a priori predict an 
individual patient’s likelihood of response to either 
therapy, allowing the treating physician to precisely 
match the patient to the treatment with highest 
likelihood of beneﬁ t.
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